DGAP-Adhoc: Vita 34 AG: Positive Development of Business in the First Nine Months of 2014


Vita 34 AG  / Key word(s): 9-month figures

23.10.2014 07:33

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Vita 34 AG: Positive Development of Business in the First Nine Months of
2014

Leipzig, 23 October 2014 - Vita 34 AG (WKN A0BL84), the largest private
stem cell bank in the German-speaking countries, published its financial
figures for the first nine months of fiscal year 2014 today. In accordance
herewith revenues increased as compared with the prior year's period by 1.7
percent from EUR 9.9 million to EUR 10.1 million. The total operating
income in the reporting period rose by 2.4 percent to EUR 10.8 million
(prior year: EUR 10.6 million). Thanks to increased revenues and
optimization measures implemented in marketing and sales, the earnings
before interest, taxes, depreciation and amortization (EBITDA) rose to EUR
1.6 million in the first nine months and were, therefore, 7.2 percent over
the value of the prior year's period, which was EUR 1.5 million. EBIT
increased by 25.8 percent to EUR 0.8 million (prior year: EUR 0.7 million).
The period result of EUR 0.4 million was 52.5 percent higher than the prior
year's value of EUR 0.3 million. Thus, the earnings per share improved to
EUR 0.16 (prior year: EUR 0.11).

On account of the delayed issuance during the year of official approvals
for the collection of umbilical cord tissue, the Management Board estimates
the operating profit (EBITDA) for the entire year 2014 will be below
previous expectations, however, that it will be higher than the prior
year's level. With the further issuance of official permits for the
collection and storage of umbilical cord tissue, an increasing positive
trend with regard to the development of revenues and profits is to be
expected for 2015.

Additional information:

ISIN: DE000A0BL849
WKN: A0BL84
Ticker symbol: V3V
Market segment: Regulated Market (Prime Standard) of the Frankfurt Stock
Exchange

Vita 34 AG
Deutscher Platz 5
04103 Leipzig
Germany

END OF THE AD-HOC NOTICE

 


23.10.2014 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Vita 34 AG
              Deutscher Platz 5a
              04103 Leipzig
              Germany
Phone:        +49(0341)48792-40
Fax:          +49(0341)48792-39
E-mail:       ir@vita34.de
Internet:     www.vita34.de
ISIN:         DE000A0BL849
WKN:          A0BL84
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, Hamburg, München, Stuttgart
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------